Introduction
Lowering of low density lipoprotein (LDL) cholesterol is accepted as a key objective in the prevention of cardiovascular disease. 1, 2 Controversies remain, however, as to which kind of subjects to treat, use of goals, the magnitude of the benefit, and potential harms especially in the context of primary prevention. [3] [4] [5] [6] Examination of the long-term (lifetime) consequences of lowering LDL cholesterol can assist greatly in understanding more fully the efficacy and safety of this intervention, and a number of studies have reported extended observations beyond the end of the formal trial. [7] [8] [9] [10] [11] In the West of Scotland Coronary Prevention Study (WOSCOPS), where follow-up was first examined approximately 10 years after the end of the 5 year trial 7 , there was evidence of further reduction in coronary events over the 15 year period and, based on the available data, no emergent safety issues. Overall, there was a reduction in all-cause mortality (hazard ratio (HR) = 0.88, 95% confidence interval (CI) (0.79-0.99), p=0.03) and in the outcome of death or hospitalisation due to coronary heart disease (HR=0.75, 95% CI (0.68-0.83), p<0.001). Further, over the 15 year period, five years of treatment with pravastatin was shown to be cost-saving in terms of overall health service costs 12 , adding an important economic dimension to the clinical outcome analysis. Previous work had shown there was a relatively low uptake of statin treatment in the first five years of extended follow-up after the trial, which means WOSCOPS is uniquely placed to investigate the legacy effects of five years of statin treatment in terms of ongoing benefit and potential safety issues later in life.
We have now increased the period of follow-up to 20 years to examine a range of mortality and morbidity outcomes as a 'first event' and as a 'total burden of disease' in the form of cumulative hospital admissions. More detailed interrogation of hospitalisation rates has allowed a fuller picture of benefits and risks to emerge. Given a mean age at randomisation of 55 evidence of further reduction in coronary events over the 15 year period and, based ed ed o o on n n th th the e e available data, no emergent safety issues. Overall, there was a reduction in all-cause mortality p< < <0. 0.00 0 0 1). Fu Fu urt r r he e er, ove e er the 15 1 15 y y year r r p p per r rio od o , , f f fiv v ve yea ea ar rs o o of f f trea ea eatm tm men n nt wi wi with p p prava va vast st statin n n w w was sh h hown n n to be be be c c cos os ost t t-sa sa savi i ving ng ng i i in n n te te term rm rms s s of of of ov o over er eral al all l l he he heal al alth th th s s ser er ervi i vice ce ce c c cos os osts ts ts 12 12 , ad ad addi di ding ng ng a a an n n im im impo po port rt rtan an ant t t ec ec econ on onom om omic ic ic years, the extended observation period -to a mean of 75 years (range 65-85 years) -gives an approximation of the lifetime benefit of this pharmacological intervention.
Methods
The design of WOSCOPS and its long-term follow-up have been described elsewhere. [13] [14] [15] It was a randomised trial of pravastatin (40mg once daily) versus placebo in men, aged 45-64 years (mean age 55 years), with raised cholesterol who had no evidence of previous myocardial infarction (based on medical history and a baseline, centrally-read electrocardiogram).
Participants had a mean (SD) plasma cholesterol level of 272 (23) en en enro o olled in th he tr tr tria i ial. T T The he he a a ave ve vera ra rag g ge f f fol ol ollo low w-w-up w w wa a as 4.9 ye ear ar ars s s (r (r (ran an ange ge, , 3. 3. 3.5 5 5 to to to 6 6.1ye ye year ar ars) s) s) w w wit it i h h h f fi fina na nal l l st st s u u udy vi i isi s s ts ts ts in Ma ay y y 1995 95 95.
Af Af Afte te ter r r th th the e e en en end d d of of of t t the he he t t tri ri rial al al, us s use e e of of of l l lip ip ipid id id l l -low o ower er erin in ing g g th th ther er erap ap apy du d duri ri ring ng ng th th the e e fi fi firs rs rst t t 5 5 5 ye e year ar ars s s of of of Committee of the National Health Service for Scotland. All participants gave informed consent to take part in the trial and to the examination of their medical records.
Previous analyses focussed on time-to-first event for deaths, incident cancers and composite cardiovascular outcomes 7, 14 and health economics evaluation. 12 In the current report
we assessed the impact on mortality, incident cancers and the cumulative number of hospital admissions over 20 years or until death. We report on hospital admissions for each of noncardiovascular causes, cardiovascular causes, coronary heart disease, myocardial infarction, heart failure, stroke and we describe the cumulative number of coronary revascularisations (coronary artery bypass graft or percutaneous coronary intervention or angioplasty).
Statistical methods
Cumulative incidence functions, accounting for the competing risk of death from other causes, were used to describe the incidence of cause-specific deaths or time to first incident cancer. To estimate treatment effects for cause-specific mortality and incident cancers Cox proportional hazards models were fitted including the treatment group and baseline risk factors -age, body mass index, systolic and diastolic blood pressures, high and low-density lipoprotein cholesterol levels, log-transformed triglyceride level, nitrate use, history of angina, history of diabetes, history of hypertension (all yes or no), smoking status (current, former, never), and a seven composite cardiovascular outcomes 7, 14 and health economics evaluation. 12 In the e e c c cur ur urre re rent nt nt r r rep ep epor or ort
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category social deprivation score. 18 Treatment effects (pravastatin versus placebo) were expressed as hazard ratios with 95% confidence intervals and corresponding p-values.
The cumulative numbers of hospital admissions of each type were presented, without adjustment for the competing risk of death, to represent the true difference in health care resource usage over 20 years (all participants had a potential follow-up of a minimum of 20 years). We also calculated the crude rates of hospital admission of each type correcting for the different total periods of follow-up in each randomised group due to the increased survival and consequent greater exposure to risk in the statin treated group. These statistics were compared using re-randomisation tests (based on 10,000 re-randomisations).
Because of the interest in the long term impact of statin treatment on diabetes and its complications, we identified all non-cardiovascular hospital admissions that were associated with diabetes or its complications, either as a reason for admission or as a factor complicating the admission. Cardiovascular admissions were omitted from this analysis because of the potential bias associated with the overall reduction in cardiovascular admissions due to statin treatment.
Similarly we reported on other non-cardiovascular hospital admissions grouped by ICD-10 codes to examine the long-term safety of statin use. These analyses were further sub-divided into daycases and non day-cases.
The data analysis for this paper was generated using SAS software, Version 9. bi i ia as a a a associa ate te ted w wi w t th t the he he over r rall ll ll red d duc u u ti i ion n n in n n ca a ardiov v vas scu u ular r r adm dm dmi i iss s sio o ons n n du ue t t to st s atin in n t t trea atm m ment t t.
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Results
The mean follow-up until censoring date or death in the pravastatin treated group was 18.6 years compared to 18.3 years for the placebo group. Baseline characteristics of the two randomised groups have been reported previously. 15 There were no differences in characteristics at baseline between the two groups including age, body mass index, blood pressure, cholesterol, alcohol use, smoking, employment and previous medical history.
Mortality
In the total period of follow-up 1253 (38%) of those originally randomised to placebo died 
Incident cancers
There was no evidence of an increased risk of overall incident cancer, 809 (24.6%) participants had events in the placebo treated group compared to 802 (24.3%) on pravastatin (p = 0.24), or of cause-specific cancers (Supplementary Table 1 , Supplementary Fig 1b) .
Cumulative hospital admissions
In the group of 3293 participants originally randomised to placebo, 1546 experienced a total of 4102 cardiovascular admissions compared to 1398 participants (out of 3302) in the pravastatin group who had 3436 admissions, p < 0.0001 ( Table 2 Th Th Ther er ere e e wa a was s s no no no e e evi i vide de denc nc nce e e of of of a a an n n in in incr cr crea ea ease se sed d d ri ri risk sk sk o o of f f o o ove e vera ra rall ll ll i i inc nc ncid id iden en ent t t ca ca canc nc ncer er er f f f , 80 80 809 9 9 (2 (2 (24 4 4.6% 6% 6%) ) ) pa pa part rt rtic ic icip ip ipan an ants ts ts (Supplementary Fig 2b) . There was a significant reduction in hospital admissions involving coronary revascularisation (percutaneous coronary intervention, coronary artery bypass surgery or angioplasty) with 1210 events in the placebo group and 1029 in the pravastatin group, p = 0.0078 (Fig 2d) .
There were numerically more non-cardiovascular admissions in the pravastatin group but the rates when adjusted for duration of follow-up were similar, 2.97 events/10 years for placebo compared to 3.03 events/10 years for pravastatin. Neither comparison achieved statistical significance. ( Table 2 , Supplementary Fig 2c) .
In a further exploration, hospitalisations were divided into day-cases and non-day cases (that is, events involving an overnight stay). Subjects in the pravastatin group had fewer hospitalisations for cardiovascular reasons in both categories ( Table 3) . Supplementary tables 2 and 3 give the frequency of non-cardiovascular admissions by ICD body system classification for day cases and non day-cases. Overall, the numbers of subjects and cumulative events were balanced between the two groups for non day-cases. For day-cases it was noted that the pravastatin group had an apparent increased risk of events associated with diseases of the eye and adnexa (p=0.03 uncorrected for multiple comparisons) which was attributable for the most part to an excess of admissions for cataract surgery (not individually statistically significant).
There were numerically more day-case events but not subjects with events associated with neoplasms and diseases of the digestive system.
Hospital admissions associated with complications of diabetes
In the placebo group, a total of 221 participants experienced 911 non-cardiovascular hospital admissions that contained a diabetes related ICD code compared to 201 participants (770 admissions) in the pravastatin treated group; hazard ratio 0.81, 95% CI 0.67 -0.98, p = 0.030. that is, events involving an overnight stay). Subjects in the pravastatin group had d d f f few ew ewer er er hospitalisations for cardiovascular reasons in both categories ( r Table 3 ). Supplementary tables 2 an n nd d d 3 3 3 g g giv iv ive e e the e fr fr frequency of non-cardiovascula a ar r r a a adm d d issions by ICD b b bod od ody system classification r r r fo fo for d day cases an n nd d d n no on n n da da ay-y-y-ca ca case se ses s s. O O Ov v ver ra rall, th th the e n n numb mbers o o of f f su su ubj bj bjec ects t t a a and nd nd c c cu umul l lat at ativ iv ive e e ev ev even n nt t ts w w wer er ere ba a ala la lan nc n ed bet et twe w w en e the tw wo w gr ro roup up ups fo fo for r n n non n n da a ay---cases s s. Fo Fo For r r da a ay-y-y-ca a as s ses s s it it t w w was s no o oted ed ed tha a at t t the pr pr prav a avas as asta ta tati ti tin n n gr gr grou o oup p p ha ha had d d an an an a a app pp ppar ar aren en ent t t in in incr cr crea ea ease se sed d d ri ri risk sk sk o o of f f ev e even en ents ts ts a a ass ss ssoc oc oci i iat at ated ed ed wit it ith h h di di dise se seas as ases es es o o of f f th th the e e ey e eye e e 
Discussion
This 20 year follow up of the West of Scotland Coronary Prevention Study identified a continued legacy benefit from 5 years of LDL cholesterol lowering with a statin through improved survival due to decreased mortality from cardiovascular causes and ongoing reduction in cardiovascular hospital admissions. Cumulative event rates are presented for both treatment arms to assess the impact of therapy on the total burden of disease. We observed a substantial and significant benefit; cumulative event rates were 18% lower for cardiovascular disease and 24% lower for myocardial infarction in the pravastatin group. Our focus on recurrent events reflects current interest in the impact of interventions on the total burden of disease. We observed also continuing divergence of the cumulative event curves for heart failure hospitalisation over 20 years with a 35% lower rate in the pravastatin arm.
Over two decades since the publication of the first successful primary prevention trial of a statin 15 , with subsequent studies 19,20 and meta-analyses 5,21,22 also confirming the benefits of LDL cholesterol reduction, there are still concerns over side effects of treatment, long-term safety, impact on all-cause mortality, and cost-effectiveness [3] [4] [5] [6] 23, 24 that lead a number of commentators to continue to express caution when wider use of statins in primary prevention strategies is promoted. 25, 26 The current study found no increased incidence of cancer overall, and enhanced site-specific data shows no imbalance between the two groups (note the balanced rates hospital admissions. Cumulative event rates are presented for both treatment arms ms ms t t to o o as as asse se sess ss ss t t the h h mpact of therapy on the total burden of disease. We observed a substantial and significant bene e efi fi fit; t; t; c c cum um umul u u at tiv iv ive e e event rates were 18% lower r f f for or or cardiovascular dise e eas as se and 24% lower for m m myo oc o ardial inf nfar ar arct tio on n n n in in t t the he he p p pr r ra av ava a asta ta tati ti tin n n grou ou up p p. Ou ur r r fo ocu cu cus s on on on rec ec ecur ur rre re rent nt nt ev vent t ts s s r re refl fl flec ec ects t t c c cur ur urre re rent nt nt n n nte te t re re rest in th h he e e im m mpa a act o o of f f inte er r rve en ention on ons on on on the e e to o otal bu u urd d den n n of f f d d dise se s as as ase. e W We obs s serv rv rved a a als ls lso co co cont nt ntin in inui i uing ng ng d d div i iver er erge ge genc nc nce e e of of of t t the he he c c cum m umul l ulat at ativ i ive e e ev e even en ent t t cu c curv r rves es es f f for or or h h hea ea eart rt rt f f fai ai ailu l lure re re u h h hos os ospi pi pita ta tali li lisa sa sati ti tion on on o o ove e ver r r 20 20 20 for prostate cancer compared to the previous report). 7 Examination of non-cardiovascular admissions to hospital also showed no differences with the exception of a possible increased risk of day-case hospital admissions associated with diseases of the eye for patients using pravastatin.
The significance of this latter finding, which should be treated cautiously due to the borderline significance and the multiple adverse effects investigated, lies in its link to historical concern that inhibition of cholesterol synthesis would be lead to risk of corneal opacity. 27, 28 Epidemiological studies have suggested both increased and decreased risk of cataracts linked to statin use. [29] [30] [31] However, these studies will not have the length of follow-up available in WOSCOPS or the benefits of randomisation in minimising confounding factors. It should be noted that any treatment that improves cardiovascular survival will inevitably result in an increase in hospital admissions for non-cardiovascular causes. We saw no evidence of this for non day-case admissions. However, the trend to increased day-case admissions including treatment for cancer but not number of participants with cancer, particularly for events associated with advancing age, in the later years of follow-up could be early evidence of this survival bias effect.
Reduction in heart failure as an outcome has been reported recently in a meta-analysis of 14 trials of statin-based LDL lowering with a risk reduction of 10%. 32 The mean duration of observation in these studies was 4.3 years. Data presented here suggest that this additional clinical benefit may be underestimated in short-term studies particularly in primary prevention.
As was noted in the report by Preiss et al 32 we found that the number of heart failure admissions was reduced in subjects who had, and in those who did not have, an antecedent myocardial infarction (data not shown). The overall mechanism by which LDL lowering leads to a reduced incidence of heart failure is not fully clear. However, we note that much of the WOSCOPS follow-up was prior to the use of troponin assays and certainly before newer high sensitive reatment that improves cardiovascular survival will inevitably result in an increa a ase se se i i in n n ho ho hosp sp spit it ital al al admissions for non-cardiovascular causes. We saw no evidence of this for non day-case admi mi iss ss ssio io ions ns ns. . . Ho H H we we weve v v r, the trend to increased day-y-y-ca ca case admissions includ ud udin in ing treatment for cancer b bu but not numb ber r r o o of pa a art rt rtic c cip ip ipan an ants ts ts w w wit it ith h h c can an anc cer, p p pa a articu ul larly y y fo fo for r r ev v ven ents t t a a ass ss ssoc oc ocia ated d d wi wi with th th a a adv dv dvan an anci ci cing ng ng a a ag ge g n n n t t the he he later y y yea e e rs s o o of fo ollo ow o -up up up c c cou o ld ld ld be e e e ea e rly y y e e eviden n nce e o o of f th h his s sur ur urvi i iva va al b b bia as e e eff ff ffe e ect.
Re Re Redu d duct ct ctio io ion n n in in in h h hea ea eart rt rt f f fai ai ailu l lure re re a a as s s an an an o o out t utco co come me me h h has as as be be been en en r r rep ep epor or orte te ted d d re re rece ce cent nt ntly l ly i i in n n a a a me me meta ta ta a a -ana na naly l lysi si sis s s of of of f assays. Hence, many of the events classed as other coronary hospitalisations would be today classed as myocardial infarction. Likewise, the reduced need for revascularisation in statin treated participants indicates lower levels of ischaemia, the repeated occurrence of which could be a mechanism for the development of heart failure.
We did not demonstrate a reduction in stroke at 20 years. There was no effect in the original trial, 15 although we did see evidence of stroke reduction in the 15 year follow up. 7 However, WOSCOPS was a primary prevention trial in relatively young subjects compared to the majority of trials in the CTTC analysis which were secondary prevention studies in participants about 10 years older at randomisation and which had shorter periods of follow-up.
22
It is difficult therefore to compare directly the findings in CTTC with extended observations made when the original treatment arms are predicted to be receiving statin therapy at the same level after the trial.
In assessing the long-term impact of interventions in primary prevention, it is essential that there is a balanced evaluation of the benefits due to reduction in cardiovascular events and the potential for adverse clinical outcomes. Muscle related side effects of statins have been studied in detail. 33 They can lead to intolerance to the medication and in rare instances rhabdomyolysis. 1, 2 Statin therapy has been shown also in a number of studies to increase the propensity to develop type-2 diabetes 34, 35 with a hazard ratio of about 1.09 compared to placebo; a similar increment in diabetes risk is associated with the use of high versus low dose statin therapy. 35 This is one of the issues raised by those concerned with the more widespread use of statins in the prevention of disease in lower risk subjects. [3] [4] [5] [6] Diabetes is defined on the basis of blood glucose levels and is a disorder associated with macrovascular but also microvascular/ non-cardiovascular complications. Statins reduce cardiovascular disease and it has been t is difficult therefore to compare directly the findings in CTTC with extended obs bs bser er erva va vati ti tion on ons s s made when the original treatment arms are predicted to be receiving statin therapy at the same eve el l l af af afte te ter r r th th the e e tria ia ial. l. l
In asses s ssi si sing t t th he he l l lon on ong-g-g-te te term rm rm i i imp mp mpac ac a t of of of in n nterve ve en ntion on ons s in in in p p pri ri ima ma mar ry ry p p pre r r v vent t tio io ion n n, i i it t t is is is e e ess s s en en enti ti tial al al h h hat at a t t the h h re is s a a a ba ala la lan nc n ed d d e e evalu u uat t ti i ion o o o of f f th h he e e ben n nef f fits d du u ue t t to red d duc c cti ti io on n i in n n ca a ard diov v vas s scula ar ar e e eve ent t ts an n nd h h he e e po po pote te tent nt ntia ia ial l l fo fo for r r ad ad adve e vers rs rse e e cl cl clin in inic ic ical al al o o out t utco co come me mes s s. Mu M Musc sc scle le le r r rel el elat at ated ed ed s s sid id ide e e ef ef effe fe fect ct cts s s of of of s s sta ta tati ti tins ns ns h h hav a ave e e be be been en en estimated that their use will prevent five incidences of myocardial infarction for every new case of diabetes. 36 In this study we were able to report also that statin treatment was associated over a 20 year follow up with significantly less hospital admissions associated with non-cardiovascular complications of diabetes. This raises the possibility that while statin use may impact on blood glucose levels this does not necessarily translate into deleterious non-cardiovascular pathologies.
It should be noted, however, that WOSCOPS was unusual in that the incidence of type 2 diabetes was lower in the actively treated arm during the original trial. 37 There are limitations to this form of long-term follow up based on electronic health records as noted previously. 7, 16 Critically, we do not know what lipid regulating therapy was being used by the participants for the last 10 years of the study and this limits interpretation of data with regard to the magnitude of the 20-year benefit. If in the second half of the extended follow up more subjects originally ascribed to placebo relative to the pravastatin arm were placed on a statin (as a result of having a coronary event or as a primary prevention measure by the GP) then the difference in event rates between the two groups would be diminished and the observed hazard ratio would be an underestimate of the long-term risk reduction attributable to statin therapy. Also, we are dependent on the stability of the population to allow comprehensive capture of hospitalisations within the healthcare information systems. However, Scotland is an area of relatively low social mobility after people reach middle age which allowed us to achieve 100% follow-up at the end of the study. We also flagged all of our participants with the death registry in England and Wales and identified only 15 deaths (0.6%) there from a total of 2398 deaths. We have no current method for identifying hospital admissions outside Scotland but do not feel this would have altered our findings. Finally, as a substantial number of participants die, analyses are complicated by competing risks.
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In conclusion, in this primary prevention trial in high risk men with raised LDL cholesterol but without a history of myocardial infarction we observed a long-term legacy benefit of LDL lowering by statin therapy. Since over the 20 years the cohort aged from an average of 55 to 75 years, the cumulative event rate is an estimate of the total burden of disease (more specifically of premature morbidity and mortality -male life expectancy in Scotland is 76.8 years) and the reduction in cardiovascular events a measure of the 'lifetime' benefit of the intervention. The reduction in cumulative cardiovascular events is substantial both numerically (with attendant economic savings) and in terms of relative risk (especially for heart failure). The observation that 5 years of statin therapy led to a prolonged risk reduction raises the issue that treatment might not need to be lifelong. That is, the legacy risk reduction following say a 5 to 10 year treatment period may be sufficient to produce a clinically meaningful benefit while limiting lifetime exposure to the drug. We cannot address this question fully using the information in the current study although it is clear that therapy would have to be maintained for subjects to experience maximum risk reduction since we did see a diminution in the treatment effect in the post-trial compared to the in-trial phases. The data on diabetes associated non-cardiovascular events indicate that further work is required to understand the clinical consequences of the statin induced rise in the incidence of this disorder. These long-term efficacy findings, particularly on all-cause mortality, and detailed safety data should allay concerns over strategies to promote the more widespread use of statins in the population.
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